Uptravi (selexipag) / J&J 
Welcome,         Profile    Billing    Logout  
 17 Diseases   8 Trials   8 Trials   676 News 


«12345678910»
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Efficacy comparison of prostacyclin analogue and prostacyclin receptor agonist as third line treatment for pulmonary arterial hypertension (Station 7) -  May 13, 2023 - Abstract #ESC2023ESC_3655;    
    in our study population, epoprostenol, treprostenil and selexipag improve both exercise capacity and haemodynamic parameters in PAH patients when used as third line therapy, with the highest efficacy in the first group and, possibly, the lowest efficacy in the latter. These results confirm the beneficial role of these drugs in PAH patients and may suggest a possible favorable role for selexipag in the management of PAH patients with a less severe disease reserving a more invasive treatment strategy with parenteral prostanoids in patients with a higher risk disease.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Practices Affecting Opsumit (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_6953;    
    Results indicate that HCPs perceive persistence to be higher than indicated by medication shipment data and highlight the importance of continuous patient engagement, improvement of patient/HCP communication, disease and treatment education, and early management of side effects. Barriers such as patients
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Successful Transition From Oral Selexipag to Treprostinil (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_6837;    
    Our case demonstrates one such successful approach for this switch. Given the improvement in the patient
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
    A Meta-analysis: Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication (Walter E. Washington Convention Center, Room 151 B (Street Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_3361;    
    P3, P4
    In this meta-analysis, treatment with PAH drugs (selexipag, macitentan, or bosentan) provided a similar reduction in morbidity/mortality risk in patients with repaired CHD-PAH when compared to the PAH population overall. This meta-analysis using data from multiple randomized trials, indicates that there is an improvement in outcomes with PAH therapy in patients with CHD-PAH and provides important evidence to guide medical management of this patient population.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Journal, Adverse events:  Quantifying side effects and caregiver burdens of pediatric pulmonary hypertension therapies. (Pubmed Central) -  Jan 26, 2023   
    We also found a large, unseen economic, emotional, and time burden of caring for a child living with PH. Further research is warranted to understand the clinical implications of these side effects to move towards labeled usage of these therapies rather than post-hoc off-label usage.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Journal:  Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension. (Pubmed Central) -  Dec 16, 2022   
    Selexipag use in pediatric PAH represents a significant addition to our therapeutic arsenal, and its use provides a meaningful improvement in quality of life compared with other prostacyclin formulations. However, when goals of care include aggressive disease management, a decision between improved quality of life and possible adverse outcomes must be considered, and its substitution should include cautious, close, long-term follow-up.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku, treprostinil palmitil inhalation (INS1009) / Insmed
    Preclinical, Journal:  Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. (Pubmed Central) -  Dec 13, 2022   
    SIGNIFICANCE STATEMENT: Treprostinil palmitil (TP) is a long-acting pulmonary vasodilator prodrug of treprostinil (TRE) formulated for inhaled administration by dry powder [treprostinil palmitil inhalation powder (TPIP)]. Comparison of the activity of TPIP, inhaled and intravenous TRE, and oral selexipag in a Sugen5416/hypoxia (Su/Hx) rat model of pulmonary arterial hypertension demonstrated that each of these drugs exert protection against the hemodynamic and histopathological changes induced by the Su/Hx challenge, with the greatest effect on these changes produced by TPIP.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Trial primary completion date:  SPHINX: A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag (clinicaltrials.gov) -  Dec 7, 2022   
    P2,  N=10, Active, not recruiting, 
    Comparison of the activity of TPIP, inhaled and intravenous TRE, and oral selexipag in a Sugen5416/hypoxia (Su/Hx) rat model of pulmonary arterial hypertension demonstrated that each of these drugs exert protection against the hemodynamic and histopathological changes induced by the Su/Hx challenge, with the greatest effect on these changes produced by TPIP. Trial primary completion date: Oct 2022 --> Apr 2023
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
    Journal:  Evidence base for specific pulmonary vasodilators in adults with congenital heart disease (Pubmed Central) -  Nov 2, 2022   
    According to the updated European (ESC 2020) guidelines for congenital heart disease in adults, in Eisenmenger patients with reduced exercise capacity (6MWT distance 450 m), a treatment strategy with initial endothelin receptor antagonist monotherapy should be considered followed by combination therapy if patients fail to improve (IIaB), in low- and intermediate-risk patients with repaired simple lesions and pre-capillary PH, initial oral combination therapy or sequential combination therapy is recommended and high-risk patients should be treated with initial combination therapy including parenteral prostanoids (IA) and endothelin receptor antagonists and phosphodiesterase 5 inhibitors may be considered in selected patients with elevated pulmonary pressure/resistance in the absence of elevated ventricular end diastolic pressure (IIbC). Only three (bosentan, macitentan and selexipag) out of seven specific pulmonary vasodilators registered in the Russian Federation have indications for pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome or pulmonary arterial hypertension associated with corrected simple congenital heart disease in the instructions for use.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Journal:  Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag:  a case report. (Pubmed Central) -  Oct 26, 2022   
    Only three (bosentan, macitentan and selexipag) out of seven specific pulmonary vasodilators registered in the Russian Federation have indications for pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome or pulmonary arterial hypertension associated with corrected simple congenital heart disease in the instructions for use. A multidisciplinary approach based on clinical evaluation, as well as pharmacological counseling and evaluation of the patient's genetic profile, might be useful for identification of patients with a high chance of drug-induced liver injury, avoiding unnecessary risks in therapy selection and prescription.
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Journal, Combination therapy:  Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients. (Pubmed Central) -  Oct 8, 2022   
    Finally, the 1-year event free survival rate was 96.7% for patients initiating the triple combination therapy within 3 years of PAH diagnosis. Triple combination therapy with selexipag was safe and effective in Chinese PAH patients, which was confirmed by acceptable tolerability, and improved exercise capacity, right heart function, risk assessment, and prognosis.
  • ||||||||||  Uptravi (selexipag) / J&J
    Enrollment change:  ACT-293987 in Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Sep 19, 2022   
    P3,  N=709, Completed, 
    Code and models are available at https://github.com/IsXudongZhang/Molormer. N=1213 --> 709
  • ||||||||||  Uptravi (selexipag) / J&J, Nippon Shinyaku
    Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2901;    
    During an average follow-up of four years, aminaphtone showed a good tolerability and safety profile along with sustained efficacy in SSc patients with secondary RP, without any disabling or serious side effect. A randomized controlled trial is desirable to better evaluate the efficacy of the drug over time